Hematological Cancer Research Investment and Education Act

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

Retrieved on:

Friday, June 2, 2023

SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical significance of minimal residual disease (MRD) assessment at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, as well as the European Hematology Association (EHA) Hybrid Congress taking place June 8-11 in Frankfurt, Germany. Data will be presented from clinical trials and real-world evidence studies using Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay for MRD assessment across a range of hematologic cancers.

Key Points:

Data will be presented from clinical trials and real-world evidence studies using Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay for MRD assessment across a range of hematologic cancers.
“Adaptive has demonstrated the value of NGS-MRD assessment in hematologic cancers.
This assessment is performed as a series of tests in clinical trials and throughout a patient’s cancer journey.
Data continues to show the potential for MRD assessment to help in the personalization of cancer care.

Umoja Biopharma to Present at the 2023 BIO International Convention

Retrieved on:

Wednesday, May 31, 2023

Convention center, Hematological Cancer Research Investment and Education Act, Rare-earth element, Hotel, Tunnel

SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematological cancers, today announced that the Company will present on its mission, pipeline, technological platforms, and partnering approach at the 2023 BIO International Convention taking place June 5-8, 2023 in Boston, MA.

Key Points:

SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematological cancers, today announced that the Company will present on its mission, pipeline, technological platforms, and partnering approach at the 2023 BIO International Convention taking place June 5-8, 2023 in Boston, MA.
Presentation Location: Boston Convention & Exhibition Center, 415 Summer St., Room 103

Acurex Biosciences Appoints Esteemed Biopharmaceutical Leader Dr. Robert Booth to its Board of Directors

Retrieved on:

Tuesday, May 30, 2023

Acurex Biosciences Corporation, a biopharmaceutical company with a mission to stop neurodegeneration before it begins, announces the appointment of renowned biopharmaceutical industry leader Dr. Robert Booth to its Board of Directors.

Key Points:

Acurex Biosciences Corporation, a biopharmaceutical company with a mission to stop neurodegeneration before it begins, announces the appointment of renowned biopharmaceutical industry leader Dr. Robert Booth to its Board of Directors.
This groundbreaking inhibitor was later licensed to Pharmacyclics, where Dr. Booth served on the Board of Directors until its acquisition by AbbVie.
On his appointment to Acurex’s board, Dr. Booth commented, "I am truly excited to join the board of Acurex Biosciences.
We are thrilled to be able to attract such an esteemed industry leader and welcome Dr. Booth to our Board of Directors."

Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection Applications for Translational Research and Precision Therapeutics

Retrieved on:

Wednesday, May 31, 2023

SOUTH SAN FRANCISCO, Calif., May 31, 2023 /PRNewswire/ -- Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications. With Tapestri® v3 chemistry, researchers can discover tiny numbers of single cells that, until now, easily escaped detection and influenced disease in invisible ways. At the same time, drug developers can use the new capabilities for a more complete understanding of their advanced therapies, potentially leading to safer, more effective medicines.

Key Points:

With Tapestri® v3 chemistry, researchers can discover tiny numbers of single cells that, until now, easily escaped detection and influenced disease in invisible ways.
The new Tapestri® v3 chemistry increases the number of cells captured per sample by up to four times compared to the prior chemistry, a notable enhancement.
Tapestri® v3 is the latest example of Mission Bio's continued focus on customer-centric product and service development.
To learn more about Mission Bio and the Tapestri® Platform, visit www.missionbio.com .

Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science

Retrieved on:

Wednesday, May 24, 2023

Diversity and inclusion of Black/African American and Hispanic patient populations in oncology clinical trials lag behind trials in all other top therapeutic areas.

Key Points:

Diversity and inclusion of Black/African American and Hispanic patient populations in oncology clinical trials lag behind trials in all other top therapeutic areas.
“Global oncology continues to discover, develop and deliver important novel treatments that benefit more patients,” says Murray Aitken, Executive Director, the IQVIA Institute for Human Data Science.
There is a growing interest for bispecific antibodies, including six compounds marketed globally for oncology and many in development for rare hematological cancers.
Cancer patient access: The global numbers of treated patients have increased annually at an average 5% over the past five years.

Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress

Retrieved on:

Friday, May 26, 2023

Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 2-6, 2023, in Chicago, Ill. and the 31st Congress of the European Hematology Association (EHA), June 8-11, 2023, in Frankfurt, Germany.

Key Points:

Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 2-6, 2023, in Chicago, Ill. and the 31st Congress of the European Hematology Association (EHA), June 8-11, 2023, in Frankfurt, Germany.
The company’s presence at ASCO 2023 will underscore Takeda’s growing solid tumor portfolio, with research focused on improving treatment for metastatic colorectal cancer (CRC), as well as rare forms of oncogene-driven non-small cell lung cancer (NSCLC).
Within its hematology portfolio, Takeda will present data in oral sessions at both ASCO and EHA on a head-to-head Phase 3 study comparing targeted treatments in newly diagnosed patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Building on decades of leadership in oncology and a portfolio of approved medicines for hematologic cancers and solid tumors, we are advancing a cutting-edge pipeline focused on the power of innate immunity.

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

Retrieved on:

Thursday, May 18, 2023

WORCESTER, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.

Key Points:

Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology.
Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.
Subject to closing, the parties will enter into a manufacturing supply agreement, under which uBriGene will manufacture Mustang’s lead product candidates, including continuing to support MB-106 manufacturing for the ongoing multi-center Phase 1/2 trial.
I want to thank our manufacturing team for their dedication in building and growing our Worcester facility since it opened in 2018.

New Computational Tool Identifies Novel Targets for Cancer Immunotherapy

Retrieved on:

Wednesday, May 17, 2023

PHILADELPHIA, May 17, 2023 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets. The tool, called "Isoform peptides from RNA splicing for Immunotherapy target Screening" (IRIS), was described in a paper published today in the Proceedings of the National Academy of Sciences.

Key Points:

"We know that aberrant alternative RNA splicing is widespread in cancer and generates a range of potential immunotherapy targets.
In our study, we were able to show that our computational platform was able to identify immunotherapy targets that arise from alternative splicing, introducing a broadly applicable framework for discovering novel cancer immunotherapy targets that arise from this process."
"This proof-of-concept study demonstrates that alternatively spliced RNA transcripts are viable targets for cancer immunotherapy and provides a big data and multiomics-powered computational platform for finding these targets," Dr. Xing added.
"IRIS: discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing," Proceedings of the National Academy of Sciences, online May 16, 2023, DOI: 10.1073/pnas.2221116120

Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity

Retrieved on:

Wednesday, May 17, 2023

UB, Gene, Drug discovery, CAR, Date, Investigational New Drug, Hematological Cancer Research Investment and Education Act, Annual general meeting, Cell, American Society of Gene and Cell Therapy, Neoplasm, Surface, MDF, Society, Vaccine, Medical imaging, Umoja, IND

SEATTLE, May 17, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced the presentation of new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting demonstrating potent in vivo CAR T cell generation and robust anti-tumor activity using its VivoVec™ platform.

Key Points:

We look forward to bringing our product candidates to the clinic in the coming year.”
Umoja’s oral and poster presentations highlight preclinical data demonstrating efficient in vivo CAR T cell generation and anti-tumor activity using its off-the-shelf surface-engineered lentiviral VivoVec platform.
Specifically, the preclinical data highlight advancements made in vector design by incorporating a multidomain fusion (MDF) protein that improves activity via multiple routes of administration.
MDF VivoVec particles demonstrate improved anti-tumor response in vivo and at a lower dose compared to particles containing separate costimulatory molecules.
MDF-engineered VivoVec particles delivered using Lupagen’s extracorporeal system generate functional CAR T cells in vivo that mediate durable anti-tumor responses in preclinical tumor xenograft models.

Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810

Retrieved on:

Tuesday, May 16, 2023

Trueline Therapeutics Inc. , an oncology-focused subsidiary of Anji Pharmaceuticals, today announced the successful completion of IND-enabling studies with MCL1 inhibitor TTX-810, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers.

Key Points:

Trueline Therapeutics Inc. , an oncology-focused subsidiary of Anji Pharmaceuticals, today announced the successful completion of IND-enabling studies with MCL1 inhibitor TTX-810, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers.
A distinguishing feature of TTX-810 is a rapid clearance profile to minimize the potential risks of sustained MCL1 inhibition in non-cancerous tissues.
“The completion of IND-enabling studies marks the culmination of over a decade’s work to truly understand the safest and most effective way to approach MCL1 inhibition,” said Ulla Rauh, Ph.D., CEO/CSO of Trueline Therapeutics.
Following candidate selection, Trueline Therapeutics scientists designed and executed the IND-enabling program in preparation for first-in-human testing.